Skip to content

Insider · CIK 0001681854

Elizabeth Crowley

officer

Files at CLDX (Celldex Therapeutics, Inc.). First filing -, latest -.

Elizabeth Crowley files SEC Form 4 as officer at CLDX (Celldex Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.

A track record needs three past buys with six months of prices behind them; Elizabeth Crowley has 0, so none is measured yet.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold

Signals

This insider’s open-market buys and sells, scored.

No scored open-market trades yet.

Transactions

Every row this insider has filed, 2 in all, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Jun 25, 2026CLDX
Celldex Therapeutics, Inc.
AGrant or award
Incentive Stock Option (right to buy)derivative
+100,000$0.00$0100,000Jun 29, 2026
Jun 5, 2025CLDX
Celldex Therapeutics, Inc.
AGrant or award
Incentive Stock Option (right to buy)derivative
+85,000$0.00$085,000Jun 9, 2025

Questions about Elizabeth Crowley

Answered from the filings on this page, as of the latest one.

Is Elizabeth Crowley buying or selling?

Elizabeth Crowley has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.

How did Elizabeth Crowley's past buys perform?

Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Elizabeth Crowley has 0.

Where does Elizabeth Crowley file Form 4?

Elizabeth Crowley has filed Form 4 at CLDX (Celldex Therapeutics, Inc.) as SR. VP & CPDO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.